Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G9JQ
|
|||
| Former ID |
DIB000717
|
|||
| Drug Name |
PB1046
|
|||
| Synonyms |
Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera
Click to Show/Hide
|
|||
| Drug Type |
Recombinant protein
|
|||
| Indication | Heart failure [ICD-11: BD10-BD13; ICD-10: I50, I50.9; ICD-9: 428] | Phase 2 | [1] | |
| Pulmonary arterial hypertension [ICD-11: BB01.0; ICD-9: 416] | Phase 2 | [2] | ||
| Cardiomyopathy [ICD-11: BC43] | Phase 1 | [3] | ||
| Duchenne dystrophy [ICD-11: 8C70; ICD-10: G71.0] | Phase 1 | [1] | ||
| Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Phase 1 | [4] | ||
| Company |
Phasebio pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Helodermin-preferring VIP receptor (VIPR2) | Target Info | Agonist | [5] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Reactome | G alpha (s) signalling events | |||
| WikiPathways | SIDS Susceptibility Pathways | |||
| GPCRs, Class B Secretin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT03795428) Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 (VIP Extend). U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of PhaseBio. | |||
| REF 5 | Clinical pipeline report, company report or official report of PhaseBio Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.